The advent of immunotherapy—including programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) immune checkpoint inhibitors—has revolutionized the therapeutic paradigm across a wide range of cancers. Here, CD274 is linked to cancer.